Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. / Haraldsson, Stefan; Klarskov, Louise; Nilbert, Mef; Bernstein, Inge; Bonde, Jesper; Holck, Susanne.

I: B M C Clinical Pathology, Bind 17, 11, 08.2017.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Haraldsson, S, Klarskov, L, Nilbert, M, Bernstein, I, Bonde, J & Holck, S 2017, 'Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X', B M C Clinical Pathology, bind 17, 11. https://doi.org/10.1186/s12907-017-0052-1

APA

Haraldsson, S., Klarskov, L., Nilbert, M., Bernstein, I., Bonde, J., & Holck, S. (2017). Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. B M C Clinical Pathology, 17, [11]. https://doi.org/10.1186/s12907-017-0052-1

Vancouver

Haraldsson S, Klarskov L, Nilbert M, Bernstein I, Bonde J, Holck S. Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. B M C Clinical Pathology. 2017 aug.;17. 11. https://doi.org/10.1186/s12907-017-0052-1

Author

Haraldsson, Stefan ; Klarskov, Louise ; Nilbert, Mef ; Bernstein, Inge ; Bonde, Jesper ; Holck, Susanne. / Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X. I: B M C Clinical Pathology. 2017 ; Bind 17.

Bibtex

@article{cce66dbfd3d04e15a5780f3b75351a31,
title = "Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X",
abstract = "BACKGROUND: Hereditary non-polyposis colorectal cancer comprises Lynch syndrome and familial colorectal cancer type X (FCCTX). Differences in genetics, demographics and histopathology have been extensively studied. The purpose of this study is to characterize their immunoprofile of markers other than MMR proteins.METHODS: We compared the expression patterns of cytokeratins (CK7 and CK20), mucins (MUC2/5 AC/6), CDX2 and β-catenin in Lynch syndrome and FCCTX.RESULTS: Differences were identified for CK20 and nuclear β-catenin, which were significantly more often expressed in FCCTX than in Lynch syndrome (p < 0.001), whereas MUC2, MUC5AC and MUC6 were overexpressed in Lynch syndrome tumors compared with FCCTX tumors (p = 0.001, < 0.01, and < 0.001, respectively). We observed no differences in the expression patterns of CK7 and CDX2.CONCLUSIONS: In summary, we identified significant differences in the immunoprofiles of colorectal cancers linked to FCCTX and Lynch syndrome with a more sporadic-like profile in the former group and a more distinct profile with frequent MUC6 positivity in the latter group.",
keywords = "Journal Article",
author = "Stefan Haraldsson and Louise Klarskov and Mef Nilbert and Inge Bernstein and Jesper Bonde and Susanne Holck",
year = "2017",
month = aug,
doi = "10.1186/s12907-017-0052-1",
language = "English",
volume = "17",
journal = "BMC Clinical Pathology",
issn = "1472-6890",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Differential expression of CK20, β-catenin, and MUC2/5AC/6 in Lynch syndrome and familial colorectal cancer type X

AU - Haraldsson, Stefan

AU - Klarskov, Louise

AU - Nilbert, Mef

AU - Bernstein, Inge

AU - Bonde, Jesper

AU - Holck, Susanne

PY - 2017/8

Y1 - 2017/8

N2 - BACKGROUND: Hereditary non-polyposis colorectal cancer comprises Lynch syndrome and familial colorectal cancer type X (FCCTX). Differences in genetics, demographics and histopathology have been extensively studied. The purpose of this study is to characterize their immunoprofile of markers other than MMR proteins.METHODS: We compared the expression patterns of cytokeratins (CK7 and CK20), mucins (MUC2/5 AC/6), CDX2 and β-catenin in Lynch syndrome and FCCTX.RESULTS: Differences were identified for CK20 and nuclear β-catenin, which were significantly more often expressed in FCCTX than in Lynch syndrome (p < 0.001), whereas MUC2, MUC5AC and MUC6 were overexpressed in Lynch syndrome tumors compared with FCCTX tumors (p = 0.001, < 0.01, and < 0.001, respectively). We observed no differences in the expression patterns of CK7 and CDX2.CONCLUSIONS: In summary, we identified significant differences in the immunoprofiles of colorectal cancers linked to FCCTX and Lynch syndrome with a more sporadic-like profile in the former group and a more distinct profile with frequent MUC6 positivity in the latter group.

AB - BACKGROUND: Hereditary non-polyposis colorectal cancer comprises Lynch syndrome and familial colorectal cancer type X (FCCTX). Differences in genetics, demographics and histopathology have been extensively studied. The purpose of this study is to characterize their immunoprofile of markers other than MMR proteins.METHODS: We compared the expression patterns of cytokeratins (CK7 and CK20), mucins (MUC2/5 AC/6), CDX2 and β-catenin in Lynch syndrome and FCCTX.RESULTS: Differences were identified for CK20 and nuclear β-catenin, which were significantly more often expressed in FCCTX than in Lynch syndrome (p < 0.001), whereas MUC2, MUC5AC and MUC6 were overexpressed in Lynch syndrome tumors compared with FCCTX tumors (p = 0.001, < 0.01, and < 0.001, respectively). We observed no differences in the expression patterns of CK7 and CDX2.CONCLUSIONS: In summary, we identified significant differences in the immunoprofiles of colorectal cancers linked to FCCTX and Lynch syndrome with a more sporadic-like profile in the former group and a more distinct profile with frequent MUC6 positivity in the latter group.

KW - Journal Article

U2 - 10.1186/s12907-017-0052-1

DO - 10.1186/s12907-017-0052-1

M3 - Journal article

C2 - 28824332

VL - 17

JO - BMC Clinical Pathology

JF - BMC Clinical Pathology

SN - 1472-6890

M1 - 11

ER -

ID: 185275982